Biocon sells US copies of 3 of the blockbuster drugs on this tracker, is approved for 3 more, and has 2 filed or in development. Those brands earned $39.6B in 2025. Of the 70 makers we follow, 10 are lined up to copy more of these drugs.
| Drug | Biocon's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Stelara YesintekBiosimilar · Johnson & Johnson · US LOE 2025 | FDA-approved 29 Nov 2024; launched 24 Feb 2025; interchangeable | 7 on sale · 0 approvedof 7 other makers listed | $6.1B |
| Prolia BosayaBiosimilar · Amgen · US LOE 2025 | FDA-approved 16 Sep 2025; launched 7 Apr 2026; interchangeable | 6 on sale · 3 approvedof 10 other makers listed | $4.4B |
| Xgeva AukelsoBiosimilar · Amgen · US LOE 2025 | FDA-approved 16 Sep 2025; launched 7 Apr 2026; interchangeable | 5 on sale · 4 approvedof 10 other makers listed | $2.1B |
| Drug | Biocon's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| EntrestoGeneric · Novartis · US LOE 2025 | FDA-approved 30 Aug 2024 | 2 on sale · 13 approvedof 15 other makers listed | $7.7B |
| XareltoGeneric · Bayer / Johnson & Johnson · US LOE 2025 | FDA-approved 14 May 2025 | 1 on sale · 17 approvedof 19 other makers listed | ≈$5.3B |
| FarxigaGeneric · AstraZeneca · US LOE 2026 | FDA-approved 6 Apr 2026 | 2 on sale · 12 approvedof 14 other makers listed | $8.4B |
| Drug | Biocon's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Perjeta PebrilzoBiosimilar · Roche · US LOE 2026 | Filed with the FDA; settled Oct 2026; US entry allowed from 2028 | 0 on sale · 1 approvedof 1 other maker listed | ≈$3.6B |
| CabometyxGeneric · Exelixis · US LOE 2031 | Filed with the FDA; settled Jul 2025 | 0 on sale · 3 approvedof 5 other makers listed | $2.1B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
The brand owner's US sales, as it reports them. They show how fast copies took the market, not Biocon's own sales. See the launch tracker →
Each row is a copy Biocon sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Biocon's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Biocon's sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: Biocon.